Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11,224 GBX | -0.23% | +3.22% | +5.92% |
03:38pm | AstraZeneca's Voydeya Approved as Add-on Therapy in Europe for Blood Disorder | MT |
10:50am | ASTRAZENECA : JP Morgan reaffirms its Buy rating | ZD |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.92% | 215B | |
+27.25% | 659B | |
+27.68% | 557B | |
-4.60% | 359B | |
+16.66% | 322B | |
+9.63% | 297B | |
+4.93% | 210B | |
-6.01% | 200B | |
-8.35% | 149B | |
-5.23% | 146B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Credit Suisse Downgrades AstraZeneca to Neutral From Outperform, Citing Valuation After Year-to-Date Stock Climb; Price Target Kept at GBP110